Literature DB >> 6695357

Invasive pulmonary aspergillosis in a non-immunosuppressed patient: successful management with systemic amphotericin and flucytosine and inhaled amphotericin.

S Rodenhuis, F Beaumont, H F Kauffman, H J Sluiter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6695357      PMCID： PMC459729          DOI： 10.1136/thx.39.1.78

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  10 in total

1.  The innocuousness and possible therapeutic use of aerosol amphotericin-B.

Authors:  K H KILBURN
Journal:  Am Rev Respir Dis       Date:  1959-09

2.  Aerosol chemotherapy in bronchopulmonary candidiasis.

Authors:  A Oehling; M Giron; M L Subira
Journal:  Respiration       Date:  1975       Impact factor: 3.580

3.  Fatal disseminated aspergillosis in an asthmatic patient treated with corticosteroids.

Authors:  K B Lake; P M Browne; J J Van Dyke; L Ayers
Journal:  Chest       Date:  1983-01       Impact factor: 9.410

4.  Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus.

Authors:  M Kitahara; V K Seth; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

5.  Case report: invasive pulmonary aspergillosis in a nonimmunosuppressed patient.

Authors:  G A Roselle; C A Kauffman
Journal:  Am J Med Sci       Date:  1978 Nov-Dec       Impact factor: 2.378

6.  Combined amphotericin B-flucytosine therapy in Aspergillus pneumonia.

Authors:  S D Codish; J S Tobias; M Hannigan
Journal:  JAMA       Date:  1979-06-01       Impact factor: 56.272

7.  Comparison of antibody measurements against Aspergillus fumigatus by means of double-diffusion and enzyme-linked immunosorbent assay (ELISA).

Authors:  H F Kauffman; F Beaumont; H Meurs; S van der Heide; K de Vries
Journal:  J Allergy Clin Immunol       Date:  1983-09       Impact factor: 10.793

8.  Invasive aspergillosis. Progress in early diagnosis and treatment.

Authors:  B D Fisher; D Armstrong; B Yu; J W Gold
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

9.  Pharmacokinetics of amphotericin B and flucytosine.

Authors:  A Polak
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401

10.  Fatal pulmonary psittacosis and aspergillosis. Case report of dual infection.

Authors:  R W Emmons; E Able; D J Tenenberg; J Schachter
Journal:  Arch Intern Med       Date:  1980-05
  10 in total
  3 in total

1.  Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease.

Authors:  L B Palmer; H E Greenberg; M J Schiff
Journal:  Thorax       Date:  1991-01       Impact factor: 9.139

2.  Chronic necrotising pneumonia caused by Aspergillus niger.

Authors:  J Wiggins; T J Clark; B Corrin
Journal:  Thorax       Date:  1989-05       Impact factor: 9.139

Review 3.  Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections.

Authors:  Kévin Brunet; Jean-Philippe Martellosio; Frédéric Tewes; Sandrine Marchand; Blandine Rammaert
Journal:  Pharmaceutics       Date:  2022-03-14       Impact factor: 6.321
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.